These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38751227)

  • 21. Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators.
    Wang H; Cao D; Gillespie JC; Mendez RE; Selley DE; Liu-Chen LY; Zhang Y
    Future Med Chem; 2021 Mar; 13(6):551-573. PubMed ID: 33590767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional selectivity and dualsteric/bitopic GPCR targeting.
    Schrage R; Kostenis E
    Curr Opin Pharmacol; 2017 Feb; 32():85-90. PubMed ID: 28027487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular mechanisms of bitopic ligand engagement with the M1 muscarinic acetylcholine receptor.
    Keov P; López L; Devine SM; Valant C; Lane JR; Scammells PJ; Sexton PM; Christopoulos A
    J Biol Chem; 2014 Aug; 289(34):23817-37. PubMed ID: 25006252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controlling the selectivity of aminergic GPCR ligands from the extracellular vestibule.
    Egyed A; Kelemen ÁA; Vass M; Visegrády A; Thee SA; Wang Z; de Graaf C; Brea J; Loza MI; Leurs R; Keserű GM
    Bioorg Chem; 2021 Jun; 111():104832. PubMed ID: 33826962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probing the Existence of a Metastable Binding Site at the β
    Gaiser BI; Danielsen M; Marcher-Rørsted E; Røpke Jørgensen K; Wróbel TM; Frykman M; Johansson H; Bräuner-Osborne H; Gloriam DE; Mathiesen JM; Sejer Pedersen D
    J Med Chem; 2019 Sep; 62(17):7806-7839. PubMed ID: 31298548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploration of the orthosteric/allosteric interface in human M1 muscarinic receptors by bitopic fluorescent ligands.
    Daval SB; Kellenberger E; Bonnet D; Utard V; Galzi JL; Ilien B
    Mol Pharmacol; 2013 Jul; 84(1):71-85. PubMed ID: 23604140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allostery at opioid receptors: modulation with small molecule ligands.
    Livingston KE; Traynor JR
    Br J Pharmacol; 2018 Jul; 175(14):2846-2856. PubMed ID: 28419415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Orthosteric Building Blocks of Bitopic Ligands for Muscarinic M1 Receptors.
    Volpato D; Kauk M; Messerer R; Bermudez M; Wolber G; Bock A; Hoffmann C; Holzgrabe U
    ACS Omega; 2020 Dec; 5(49):31706-31715. PubMed ID: 33344823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allosteric modulators targeting CNS muscarinic receptors.
    Bock A; Schrage R; Mohr K
    Neuropharmacology; 2018 Jul; 136(Pt C):427-437. PubMed ID: 28935216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts.
    Newman AH; Battiti FO; Bonifazi A
    J Med Chem; 2020 Mar; 63(5):1779-1797. PubMed ID: 31499001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bitopic Ligands Support the Presence of a Metastable Binding Site at the β
    Gaiser BI; Danielsen M; Xu X; Røpke Jørgensen K; Fronik P; Märcher-Rørsted E; Wróbel TM; Liu X; Mosolff Mathiesen J; Sejer Pedersen D
    J Med Chem; 2024 Jul; 67(13):11053-11068. PubMed ID: 38952152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bivalent ligands as specific pharmacological tools for G protein-coupled receptor dimers.
    Berque-Bestel I; Lezoualc'h F; Jockers R
    Curr Drug Discov Technol; 2008 Dec; 5(4):312-8. PubMed ID: 19075611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rational design of dualsteric GPCR ligands: quests and promise.
    Mohr K; Tränkle C; Kostenis E; Barocelli E; De Amici M; Holzgrabe U
    Br J Pharmacol; 2010 Mar; 159(5):997-1008. PubMed ID: 20136835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Dual-Target μ-Opioid Receptor and Dopamine D
    Bonifazi A; Battiti FO; Sanchez J; Zaidi SA; Bow E; Makarova M; Cao J; Shaik AB; Sulima A; Rice KC; Katritch V; Canals M; Lane JR; Newman AH
    J Med Chem; 2021 Jun; 64(11):7778-7808. PubMed ID: 34011153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allosteric Antagonism of the A
    Gao ZG; Toti KS; Campbell R; Suresh RR; Yang H; Jacobson KA
    Cells; 2020 May; 9(5):. PubMed ID: 32408534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New approaches in the design and development of cannabinoid receptor ligands: multifunctional and bivalent compounds.
    Nimczick M; Decker M
    ChemMedChem; 2015 May; 10(5):773-86. PubMed ID: 25820617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bivalent ligands for G protein-coupled receptors.
    Messer WS
    Curr Pharm Des; 2004; 10(17):2015-20. PubMed ID: 15279542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IUPHAR Review - Bivalent and bifunctional opioid receptor ligands as novel analgesics.
    Rehrauer KJ; Cunningham CW
    Pharmacol Res; 2023 Nov; 197():106966. PubMed ID: 37865129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists.
    Furman CA; Roof RA; Moritz AE; Miller BN; Doyle TB; Free RB; Banala AK; Paul NM; Kumar V; Sibley CD; Newman AH; Sibley DR
    Eur Neuropsychopharmacol; 2015 Sep; 25(9):1448-61. PubMed ID: 25583363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile.
    Dietis N; Guerrini R; Calo G; Salvadori S; Rowbotham DJ; Lambert DG
    Br J Anaesth; 2009 Jul; 103(1):38-49. PubMed ID: 19474215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.